News


July 18, 2008

Important update by the GOC for its membership and medical community


Concern:
New screening test for ovarian cancer “OvaSureTM

Background: Early diagnosis of ovarian cancer could significantly decrease morbidity and mortality from ovarian cancer.

History: In March 2005 Mor et al. reported on a combined blood test for leptin, prolactin, osteopontin, and IGF-II that could discriminate ovarian cancer patients from controls with a 95% sensitivity and specificity. In February of 2008, the same group reported that addingMIF and CA-125 testing to the panel increased the sensitivity to 95.3% and the specificity to 99.4%.


OvaSureTM:
Since June 2008, Laboratory Corporation of America has been offering this combination test for ovarian cancer screening to assess the presence of early stage ovarian cancer at a cost of $180-$240 in the United States. The Society of Gynecologic Oncologists (SGO) in the US has commented on it on their website ³Statement Regarding the OvaSure Product³. The Society of Gynecologic Oncologists of Canada (GOC), in collaboration with Ovarian Cancer Canada, considers this an important matter for investigation and will keep you informed of new developments. Until then, the GOC Executive does not recommend this test for routine clinical care.


Serum protein markers for early detection of ovarian cancer.

Gil Mor et al. PNAS 2005; 102 (21): 7677-82


Diagnostic Markers for Early Detection of Ovarian Cancer

Irene Visintin et al. Clin Cancer Res 2008;14(4): 1065-72


Sincerely,


Your GOC Executive,



Marie Plante, MD, GOC President

Barry Rosen, MD, GOC Past-President

Michael Fung-Kee-Fung, M.B., BS, GOC President-Elect

Walter Gotlieb, MD,PhD, GOC Secretary-Treasurer